Skip to main navigation Skip to main content Skip to page footer

Infections par le virus de l’herpès

Informations cliniques

La famille des herpèsvirus comprend plus de 100 types de virus différents, dont huit peuvent entraîner des infections chez l’homme. Outre les virus herpès simplex de type 1 et 2 (HSV-1 et -2), le virus varicelle-zona (VZV), le virus d’Epstein-Barr (EBV), le cytomégalovirus (CMV), les herpèsvirus humains 6 et 7 (HHV-6 et -7) et l’herpèsvirus humain 8 associé au sarcome de Kaposi (HHV-8) font partie de ces herpèsvirus dits humains. Malgré la grande similitude structurelle des différents agents pathogènes, les infections au virus de l’herpès peuvent provoquer des maladies très différentes, par exemple l’herpès labial ou génital, la varicelle, le zona, la mononucléose infectieuse ainsi que différents types de cancer. Pendant la grossesse, les primo-infections par certains herpèsvirus peuvent notamment entraîner de graves lésions ou la perte de l’enfant. Jusqu’à présent, il n’existe un vaccin que contre le VZV. Après la primo-infection, qui passe souvent inaperçue sur le plan clinique, les virus de l’herpès persistent à l’état latent dans l’organisme pendant toute la vie. Ils peuvent être réactivés plus tard, par exemple par un système immunitaire affaibli, et provoquer (à nouveau) des symptômes de maladie.

Diagnostic

Le diagnostic de laboratoire des infections à herpèsvirus repose sur des méthodes de détection directes et indirectes. Les méthodes directes, qui sont particulièrement importantes dans le diagnostic des infections aiguës ou de l’immunodéficience, comprennent par exemple les cultures virales ou les tests basés sur la PCR pour la détection des acides nucléiques viraux. Les échantillons peuvent être du liquide vésiculaire, des frottis de peau ou de muqueuse, du sang, du liquide céphalorachidien ou du lavage broncho-alvéolaire. En revanche, la détermination des anticorps spécifiques de l’herpèsvirus dans le sérum, le plasma ou le liquide céphalorachidien du patient constitue une détection indirecte de l’agent pathogène. La détermination des anticorps permet non seulement de savoir quel virus se trouve dans le corps du patient, mais peut également aider à distinguer les infections primaires des infections récurrentes. Pour le diagnostic des infections à herpèsvirus, EUROIMMUN propose une large gamme de produits, tant pour la détermination des anticorps que pour la détection directe de l’agent pathogène.

Methods
Technology Parameter Substrate Species Calibration Ig Class Format Order No.
ELISA CSQ pair of controls
anti-Cytomegalovirus (IgG)
IgG 02 x 20
CK 2570-0220-L G
ELISA CSQ pair of controls
anti-EBV-CA (IgG)
IgG 02 x 20
CK 2791-0220-L G
ELISA CSF: Anti-CMV ELISA (IgG)
cytomegalovirus
Sample type: CSF/serum pair
antigen-coated
microplate wells
native antigens
from CMV
5/25/50/100 U IgG 96 x 01
EI 2570-9601-L G
ELISA CSF: Anti-EBV-CA-ELISA (IgG)
Epstein-Barr virus capsid antigen
Sample type: CSF/serum pair
antigen-coated
microplate wells
native, mixture of several
viral capsid antigens
5/25/50/100 U IgG 96 x 01
EI 2791-9601-L G
ELISA CSQ pair of controls
anti-HSV-1/2 Pool (IgG)
IgG 02 x 20
CK 2531-0220-1 L G
ELISA CSF: Anti-HSV-1/2 Pool ELISA (IgG)
herpes simplex virus
Sample type: CSF/serum pair
antigen-coated
microplate wells
native antigens
from HSV-1 and HSV-2
5/25/50/100/175/230 U/ml IgG 96 x 01
EI 2531-9601-1 L G
ELISA CSQ pair of controls
anti-VZV (IgG)
IgG 02 x 20
CK 2650-0220-L G
IIFT HHV-6 infected cells EU 30 IgG
IgM
IgG
IgM
IgG
IgM
IgG
IgM
10 x 05
10 x 05
10 x 10
10 x 10
20 x 05
20 x 05
20 x 10
20 x 10
FI 2536-1005 G
FI 2536-1005 M
FI 2536-1010 G
FI 2536-1010 M
FI 2536-2005 G
FI 2536-2005 M
FI 2536-2010 G
FI 2536-2010 M
IIFT Epstein-Barr
virus capsid antigen
(EBV-CA)
expressing cells P3HR1 IgG EB
IgM EB
IgG EB
IgM EB
IgM EB
IgG EB
10 x 05
10 x 05
10 x 10
10 x 10
20 x 05
20 x 10
FI 2791-1005 G
FI 2791-1005 M
FI 2791-1010 G
FI 2791-1010 M
FI 2791-2005 M
FI 2791-2010 G
IIFT Epstein-Barr virus
nuclear antigen (EBNA,
complement-fixing antibodies)
expressing cells Raji C3c EB 10 x 10
FI 2793-1010 C
IIFT Epstein-Barr
virus early antigen
(EBV-EA)
expressing cells EU 33 IgG EB
IgG EB
10 x 05
10 x 10
FI 2795-1005 G
FI 2795-1010 G
IIFT BIOCHIP
Sequence EBV
fields A and B: EBV-CA (IgG)
field C: EBV-CA (IgM)
field D: EBV-EA
field E: EBNA


expressing cells
expressing cells
expressing cells
expressing cells


P3HR1
P3HR1
EU 33
Raji
Aviditätsbestimmung
Aviditätsbestimmung
Aviditätsbestimmung
Aviditätsbestimmung
10 x 01
10 x 02
20 x 01
20 x 02
FI 2799-1001-1 X
FI 2799-1002-1 X
FI 2799-2001-1 X
FI 2799-2002-1 X
IIFT EUROPLUS
BIOCHIP Sequence EBV
field A: EBV-CA (IgG), gp125 ag, p19 ag

field B: EBV-CA (IgG)
field C: EBV-CA (IgM), gp125 ag, p19 ag

field D: EBV-EA
field E: EBNA


expr. cells, gp125/p19/
ag-free BIOCHIP
expressing cells
expressing cells
expr. cells, gp125/p19/
ag-free BIOCHIP
expressing cells


P3HR1, native/rec.
EU 120
P3HR1
P3HR1, native/rec.
EU 120
EU 33
Raji
Aviditätsbestimmung
Aviditätsbestimmung
Aviditätsbestimmung
Aviditätsbestimmung
10 x 01
10 x 02
20 x 01
20 x 02
FI 2799-1001-21 X
FI 2799-1002-21 X
FI 2799-2001-21 X
FI 2799-2002-21 X
IIFT HHV-6 EUROPattern infected cells EU 30 IgG EB
IgM EB
IgG EB
IgM EB
IgG EB
IgM EB
IgG EB
IgM EB
10 x 05
10 x 05
10 x 10
10 x 10
20 x 05
20 x 05
20 x 10
20 x 10
FR 2536-1005 G
FR 2536-1005 M
FR 2536-1010 G
FR 2536-1010 M
FR 2536-2005 G
FR 2536-2005 M
FR 2536-2010 G
FR 2536-2010 M
ELISA Anti-EBV-CA ELISA (IgA)
Epstein-Barr virus capsid antigen
antigen-coated
microplate wells
native, mixture of several
viral capsid antigens
semi-quantitative IgA 96 x 01
EI 2791-9601 A
ELISA Anti-EBV-CA ELISA (IgG)
Epstein-Barr virus capsid antigen
antigen-coated
microplate wells
native, mixture of several
viral capsid antigens
2/20/200 RU/ml IgG 96 x 01
EI 2791-9601 G
ELISA Anti-EBV-CA ELISA (IgM)
Epstein-Barr virus capsid antigen
antigen-coated
microplate wells
native gp125
of EBV
semi-quantitative IgM 96 x 01
EI 2791-9601 M
ELISA Avidity: Anti-EBV-CA-ELISA (IgG)
Epstein-Barr virus capsid antigen
avidity determination
antigen-coated
microplate wells
native, mixture of several
viral capsid antigens
2/20/200 RU/ml IgG 96 x 01
EI 2791-9601-1 G
ELISA Anti-EBNA-1 ELISA (IgG)
Epstein-Barr virus nuclear antigen
antigen-coated
microplate wells
recombinant
EBNA-1 from EBV
2/20/200 RU/ml IgG 96 x 01
EI 2793-9601 G
ELISA Anti-EBV-EA-D ELISA (IgA)
Epstein-Barr virus early antigen
antigen-coated
microplate wells
recombinant early antigen D
from EBV
semi-quantitative IgA 96 x 01
EI 2795-9601 A
ELISA Anti-EBV-EA-D ELISA (IgG)
Epstein-Barr virus early antigen
antigen-coated
microplate wells
recombinant early antigen D
from EBV
2/20/200 RU/ml IgG 96 x 01
EI 2795-9601 G
ELISA Anti-EBV-EA-D ELISA (IgM)
Epstein-Barr virus early antigen
antigen-coated
microplate wells
recombinant early antigen D
from EBV
semi-quantitative IgM 96 x 01
EI 2795-9601 M
EUROLINE positive control serum: IgG, human, 50x concentrated
for EBV-Profil 2 G
IgG 05 x 07
CL 2790-0507-12 G
EUROLINE positive control serum: IgM, human, 50x concentrated
for EBV-Profil 2 M
IgM 05 x 07
CL 2790-0507-12 M
EUROLINE EUROLINE Anti-EBV Profile 2 (IgM)
(VCA gp125, VCA p19,
EBNA-1, p22, EA-D separately)
EUROLINE IgM
IgM
IgM
05 x 10
16 x 01
64 x 01
DN 2790-0510-2 M
DN 2790-1601-2 M
DN 2790-6401-2 M
EUROLINE EUROLINE Anti-EBV (IgM)
(VCA gp125, VCA p19, EA-D separately)
EUROLINE IgM
IgM
IgM
05 x 10
16 x 01
64 x 01
DN 2790-0510-4 M
DN 2790-1601-4 M
DN 2790-6401-4 M
EUROLINE EUROLINE Anti-EBV Profile 2 (IgG)
(VCA gp125, VCA p19,
EBNA-1, p22, EA-D separately)
EUROLINE IgG
IgG
IgG
16 x 01
50 x 01
64 x 01
DN 2790-1601-2 G
DN 2790-5001-2 G
DN 2790-6401-2 G
EUROLINE EUROLINE Anti-EBV (IgG)
(VCA gp125, VCA p19, EBNA-1, p22. EA-D separately)
EUROLINE IgG
IgG
IgG
16 x 01
50 x 01
64 x 01
DN 2790-1601-4 G
DN 2790-5001-4 G
DN 2790-6401-4 G
ChLIA IDS EBV VCA IgG antigenic coated magnetic particles Capsid antigen quantitative
100 x 01
IS-ID58011
ChLIA IDS EBV VCA IgM antigenic coated magnetic particles Capsid antigen quantitative
100 x 01
IS-ID58021
ChLIA IDS EBV EBNA-1 IgG antigenic coated magnetic particles EBNA-1 quantitative
100 x 01
IS-ID58031
ChLIA IDS EBV EA IgG antigenic coated magnetic particles EA-D antigen quantitative
50 x 01
IS-ID58041
ChLIA IDS EBV Control Set 3 x 1.5 ml Control 1/2 human serum 2 concentrations
IS-ID58301
ChLIA Anti-EBV-CA ChLIA (IgG)
Epstein-Barr virus capsid antigen
Antigen-coated magnetic particles recombinant
p18, p23, gp125
quantitative IgG 100 x 1
LI 2791-10010 G
ChLIA Anti-EBV-CA ChLIA (IgM)
Epstein-Barr virus capsid antigen
Antigen-coated magnetic particles recombinant
p18, gp125
quantitative IgM 100 x 1
LI 2791-10010 M
ChLIA Anti-EBNA-1 ChLIA (IgG)
Epstein-Barr virus nuclear antigen
Antigen-coated magnetic particles recombinant
EBNA-1
quantitative IgG 100 x 1
LI 2793-10010 G
ChLIA Control set Anti-EBV-CA ChLIA (IgG)
Epstein-Barr virus capsid antigen
2 x 0.5 ml control 1/2 IgG 02 x 02
LR 2791-20210 G
ChLIA Control set Anti-EBV-CA ChLIA (IgM)
Epstein-Barr virus capsid antigen
2 x 0.5 ml control 1/2 IgM 02 x 02
LR 2791-20210 M
ChLIA Control set Anti-EBNA-1 ChLIA (IgG)
Epstein-Barr virus nuclear antigen
2 x 0.5 ml control 1/2 IgG 02 x 02
LR 2793-20210 G
MICROBLOT EUROMicroblot Anti-EBV (IgG) IgG 96 x 01
KN 2790-9601 G
MICROBLOT EUROMicroblot Anti-EBV (IgM) IgM 96 x 01
KN 2790-9601 M
ELISA Anti-CMV ELISA (IgG)
cytomegalovirus
antigen-coated
microplate wells
native antigens
from CMV
2/20/200 RU/ml IgG 96 x 01
EI 2570-9601 G
ELISA Anti-CMV ELISA (IgM)
cytomegalovirus
antigen-coated
microplate wells
native antigens
from CMV
semi-quantitative IgM 96 x 01
EI 2570-9601 M
ELISA Avidity: Anti-CMV ELISA (IgG)
cytomegalovirus
avidity determination
antigen-coated
microplate wells
native antigens
from CMV
2/20/200 RU/ml IgG 96 x 01
EI 2570-9601-1 G
ELISA Anti-CMV p52 ELISA (IgM)
cytomegalovirus
p52 antigen from CMV
antigen-coated
microplate wells
native antigens
from CMV
semi-quantitative IgM 96 x 01
EI 2570-9601-2 M
ELISA Anti-CMV gB ELISA (IgG)
cytomegalovirus glycoprotein B
glycoprotein B antigen from CMV
antigen-coated
microplate wells
recombinant
glycoprotein B antigen from CMV
2/20/200 RU/ml IgG 96 x 01
EI 2570-9601-3 G
EUROLINE positive control serum: IgG, human, 50x concentrated
for CMV
IgG 05 x 07
CL 2570-0507 G
EUROLINE positive control serum: IgM, human, 50x concentrated
for CMV
IgM 05 x 07
CL 2570-0507 M
EUROLINE EUROLINE Anti-CMV (IgG) EUROLINE IgG
IgG
IgG
16 x 01
50 x 01
64 x 01
DN 2570-1601-2 G
DN 2570-5001-2 G
DN 2570-6401-2 G
EUROLINE EUROLINE Anti-CMV (IgM) EUROLINE IgM
IgM
IgM
16 x 01
50 x 01
64 x 01
DN 2570-1601-2 M
DN 2570-5001-2 M
DN 2570-6401-2 M
ChLIA IDS CMV IgG antigenic coated magnetic particles CMV antigen qualitative
100 x 01
IS-ID54011
ChLIA IDS CMV IgM antigenic coated magnetic particles CMV antigen qualitative
100 x 01
IS-ID54021
ChLIA IDS CMV Control Set 3 x 1.5 ml Control 1/2 human serum 2 concentrations
IS-ID54301
ChLIA IDS CMV IgG Avidity antigenic coated magnetic particles CMV antigen qualitative
50 x 01
IS-ID55011
ChLIA IDS CMV Avidity Control Set 3 x 1.0 ml Control 1/2 human serum 2 concentrations
IS-ID55301
ELISA Anti-HSV-1/2 Pool ELISA (IgG)
herpes simplex virus
native antigens from HSV-1 and HSV-2
antigen-coated
microplate wells
native antigens
from HSV-1 and HSV-2
2/20/200 RU/ml IgG 96 x 01
EI 2531-9601-1 G
ELISA Anti-HSV-1/2 Pool ELISA (IgM)
herpes simplex virus
native antigens from HSV-1 and HSV-2
antigen-coated
microplate wells
native antigens
from HSV-1 and HSV-2
semi-quantitative IgM 96 x 01
EI 2531-9601-1 M
ELISA Anti-HSV-1 (gC1) ELISA (IgG)
herpes simplex virus 1
recombinant glycoprotein C1 from HSV-1
antigen-coated
microplate wells
recombinant
glycoprotein C1
2/20/200 RU/ml IgG 96 x 01
EI 2531-9601-2 G
ELISA Anti-HSV-2 (gG2) ELISA (IgG)
herpes simplex virus 2
recombinant glycoprotein G2 from HSV-2
antigen-coated
microplate wells
recombinant
glycoprotein G2
2/20/200 RU/ml IgG 96 x 01
EI 2532-9601-2 G
WESTERNBLOT antibodies against Herpes simplex virus (HSV)
IgG positive control
IgG 50 x 05
CW 2531-5005 G
WESTERNBLOT Anti-HSV-1 / HSV-2 gG-2 EUROLINE-WB (IgG)
Herpes simplex virus 1 (HSV-1) plus HSV-2 type-specific glycoprotein G2
Westernblot whole antigen, SDS extract of HSV-1
plus purified gG2
IgG 16 x 01
DY 2531-1601-1 G
WESTERNBLOT Anti-HSV-1 / HSV-2 gG-2 EUROLINE-WB (IgM)
Herpes simplex virus 1 (HSV-1) plus HSV-2 type-specific glycoprotein G2
Westernblot whole antigen, SDS extract of HSV-1
plus purified gG2
IgM 16 x 01
DY 2531-1601-1 M
ChLIA IDS HSV-1 IgG antigenic coated magnetic particles gG1 antigen quantitative
100 x 01
IS-ID56011
ChLIA IDS HSV-2 IgG antigenic coated magnetic particles gG2 antigen quantitative
100 x 01
IS-ID56021
ChLIA IDS HSV 1/2 IgG Control Set 3 x 1.5 ml Control 1/2 human serum 2 concentrations
IS-ID56301
ChLIA IDS HSV 1/2 IgM antigenic coated magnetic particles gG1 and gG2 antigens quantitative
100 x 01
IS-ID57011
ChLIA IDS HSV 1/2 IgM Control Set 3 x 1.5 ml Control 1/2 human serum 2 concentrations
IS-ID57301
ChLIA Anti-Herpes simplex virus 1 ChLIA (IgG) Antigen-coated magnetic particles recombinant gG1 quantitative IgG 100 x 1
LI 2531-10010 G
ChLIA Anti-Herpes simplex virus 2 ChLIA (IgG) Antigen-coated magnetic particles rekombinant gG2 quantitative IgG 100 x 1
LI 2532-10010 G
ChLIA Control set Anti-HSV 1 ChLIA (IgG) 2 x 0.5 ml control 1/2 IgG 02 x 02
LR 2531-20210 G
ChLIA Control set Anti-HSV 2 ChLIA (IgG) 2 x 0.5 ml control 1/2 IgG 02 x 02
LR 2532-20210 G
IIFT Varicella zoster virus
(VZV)
infected cells EU 168 IgG
IgM
IgG
IgM
10 x 05
10 x 05
10 x 10
10 x 10
FI 2650-1005 G
FI 2650-1005 M
FI 2650-1010 G
FI 2650-1010 M
ELISA Anti-VZV ELISA (IgA)
Varicella zoster virus
antigen-coated
microplate wells
native antigens
from VZV
semi-quantitative IgA 96 x 01
EI 2650-9601 A
ELISA Anti-VZV ELISA (IgG)
Varicella zoster virus
antigen-coated
microplate wells
native antigens
from VZV
10/100/500/5000 IU/l IgG 96 x 01
EI 2650-9601 G
ELISA Anti-VZV ELISA (IgM)
Varicella zoster virus
antigen-coated
microplate wells
native antigens
from VZV
semi-quantitative IgM 96 x 01
EI 2650-9601 M
ELISA Avidity: Anti-VZV ELISA (IgG)
Varicella zoster virus
avidity determination
antigen-coated
microplate wells
native antigens
from VZV
10/100/500/5000 IU/l IgG 96 x 01
EI 2650-9601-1 G
ELISA Anti-VZV ELISA 2.0 (IgG)
Varicella zoster virus
antigen-coated
microplate wells
native antigens from VZV IgG 96 x 01
EI 2650-9601-2 G
ELISA Anti-VZV Glycoprotein ELISA (IgM)
Varicella zoster virus
antigen-coated
microplate wells
native glycoproteins
from VZV
semi-quantitative IgM 96 x 01
EI 2650-9601-2 M
ChLIA IDS VZV IgG antigenic coated magnetic particles VZV virus antigen quantitative
50 x 01
IS-ID59031
ChLIA IDS MMV IgG Control Set 3 x 1.5 ml Control 1/2 human serum 2 concentrations
IS-ID59301
ChLIA IDS VZV IgM antigenic coated magnetic particles VZV virus antigen quantitative
50 x 01
IS-ID60031
ChLIA IDS MMV IgM Control Set 3 x 1.5 ml Control 1/2 human serum 2 concentrations
IS-ID60301
* For research use only, not for in vitro diagnostic use in the sense of EU directive 98/79/EC.
1 Product manufactured by third party. Please contact your local Euroimmun representative for more information.